Experts Matter. Find Yours.
Connect for media, speaking, professional opportunities & more.
Cesar Dominguez, a fourth-year chemistry and physics double major at the University of Florida, may be on track to finding alternatives to plastic that could benefit the planet. His impactful work has helped him earn the title of Michelin Science Scholar, and he is now one of a select group of undergraduates connecting scientific research to real-world challenges at Michelin – a global leader in materials science and sustainability. “There’s always this misconception that academic research is completely separate from industry research,” Dominguez said. “Michelin has shown me it’s all one science. You can push discovery forward in both spaces.” Dominguez embarked this fall on a two-semester program of faculty-mentored research, with a $2,000 student stipend and $500 in support funding for his faculty mentor, UF chemistry professor Austin Evans, Ph.D. The program also invites students to present their findings at a spring symposium and tour a Michelin facility in South Carolina. Austin Evans' research aims to control macromolecular structure at all length scales concurrently and deploy materials in the real world. View his profile here Dominguez is furthering his study of how to process ultra-high molecular weight polymers – materials he compares to the scale of “an entire city” rather than a football stadium, through powerful electric fields. By adjusting electrospinning techniques, Dominguez and his team examine how polymers form fibers with different thermal and mechanical properties. These findings could lead to stronger, more sustainable materials, including alternatives to plastics like the major pollutant polyethylene. “All my life, I’ve been told chemistry and physics are separate fields,” Dominguez said. “But I’ve learned they come together in really elegant ways. Being able to unite concepts from both gives me a deeper understanding of how things work.” Dominguez attributes much of his development as a researcher to his work with Evans, who he describes as incredibly supportive, always accessible, and consistently encouraging him to focus on precision and detail. Dominguez also sees UF’s resources as pivotal to his journey. “I feel like what makes the research I'm doing really exciting is the fact that this can only be done at the University of Florida, because we're working with materials that have been developed by scientists here, using equipment that we're very fortunate to have access to here,” Dominguez said. As he prepares to apply to graduate school in analytical chemistry, Dominguez said the Michelin program has expanded his view of what is possible after his degree. “I used to think research only happened in academia,” he said. “Now I know industry is just as vital. It’s opened my mind to different paths for my future.” For now, he offers one piece of advice to other students considering the program: “Do it for the love of the game. If you put passion into your work, everything else will follow.” For more information on the Michelin Science Scholars Program, click here: To learn more about the research happening at UF and to connect with Austin Evans - simply click his icon now to arrange an interview today.
How LSU is Helping Keep Louisiana at the Center of the Nation’s Seafood Map
1. Strengthening the Seafood Workforce Through outreach programs like Louisiana Fisheries Forward, a partnership between Louisiana Sea Grant and the Louisiana Department of Wildlife and Fisheries, LSU helps fishers and processors modernize their operations. These voluntary programs teach best practices in handling, traceability, and sustainability — directly improving product quality and market reputation. LSU’s extension agents also provide hands-on disaster recovery assistance after hurricanes and market disruptions, helping ensure Louisiana’s seafood workforce remains resilient and ready for the next season. 2. Building Seafood Resilience The total economic value for oysters in 2018 was more than $180 million. Resilience defines LSU’s seafood science. Researchers at the LSU AgCenter and Louisiana Sea Grant are leading selective breeding programs and developing genetic tools to combat disease, temperature changes, and salinity stress. With a powerful combination of hatchery capacity, genetics expertise, and industry collaboration, LSU is helping Louisiana’s seafood industry adapt faster and smarter — protecting both the food supply and the economic backbone of coastal communities. 3. Powering Economic Growth Every part of LSU’s seafood research and outreach ties directly to Louisiana’s economy. AgCenter economists analyze market data and advise state and federal partners on strategies to grow the seafood sector. Meanwhile, Sea Grant specialists help entrepreneurs develop value-added seafood products, from branded lines to ready-to-eat options, that increase profit margins and create new jobs in coastal towns. By helping Louisiana seafood businesses stay competitive, LSU keeps more of the industry’s economic benefits right here at home. 4. Supporting Communities Louisiana’s seafood industry faces constant challenges. LSU’s coastal extension agents and Sea Grant programs provide on-the-ground support to help communities recover and rebuild after disasters. Whether assisting with dock repairs, connecting fishers to relief programs, or helping restart operations, LSU’s commitment ensures that Louisiana’s coastal workforce can weather any storm. 5. Preparing the Next Generation LSU’s work extends from the lab to the dock — and into the classroom. New research and education programs are training future scientists, producers, and entrepreneurs to continue Louisiana’s seafood legacy. For new LSU students interested in the coast, Bayou Adventure, a trip created by the College of the Coast & Environment (CC&E), was designed specifically to educate incoming freshmen about some of the challenges and marvels of the Louisiana coastline. The trip stops at sites that showcase "not just the significance of these areas to the state and nation, but the important work that is being done to sustain and preserve them," said Clint Willson, dean of CC&E. Through workforce development, hands-on learning, and applied research, LSU is shaping the next wave of innovators who will protect Louisiana’s coast and ensure its seafood remains world-renowned. Looking Ahead As the seafood industry faces new challenges and opportunities, LSU’s mission remains clear: to protect Louisiana’s coast, empower its seafood workforce, and ensure the state remains synonymous with the best seafood in America.
LSU Launches Louisiana’s Most Advanced Microscope at Research Core Facility
LSU’s Advanced Microscopy and Analytical Core (AMAC) facility gives Louisiana researchers access to 16 state-of-the-art instruments, including a new Spectra 300 Scanning Transmission Electron Microscope (S/TEM) for atomic-scale imaging and analysis. The new microscope—the most advanced in Louisiana—was installed with $10 million in support from the U.S. Army. Standing almost 13 feet tall on a platform isolated from vibration, the S/TEM required major renovations, including a raised ceiling, acoustic wall panels, and a magnetic field cancellation system to ensure the instrument’s stability and performance. The microscope offers magnification up to 10 million times, powerful enough to enlarge a single grain of Mississippi River silt to the size of Tiger Stadium. “This is a transformational moment for LSU and for the future of research in Louisiana,” Interim LSU President Matt Lee said. “With the installation of the most advanced microscope in the state, LSU is once again demonstrating how we’re delivering on our promises—leading in research, innovation, and service to the state and nation.” The launch of the AMAC and S/TEM demonstrates LSU’s increased investment in providing its faculty and partners with the best possible equipment for research and discovery, including for national defense, energy, and health. “Winning in research is no different than winning in athletics—the best facilities attract the best talent, and you need the best of both to win,” LSU Vice President of Research and Economic Development Robert Twilley said. “Today’s launch is about a state-of-the-art microscope but also the launch of the AMAC as our first research core facility at LSU—the first of more to come to attract, train, and supply the best research talent for Louisiana and build research teams that win.” Using a finely focused electron beam and techniques such as energy dispersive X-ray spectroscopy (EDS) and electron energy loss spectroscopy (EELS), the S/TEM can reveal both structure and chemistry at atomic resolution. These capabilities drive advances in materials science—improving semiconductors, solar cells, batteries, catalysts, coatings, and alloys—while supporting biomedical research by mapping drug delivery, uncovering the structures of viruses and bacteria, and improving medical implant design. LSU’s AMAC research core facility was recently rebranded, changing its name from the Shared Instruments Facility (SIF). Learn more about how AMAC instruments help unlock millions in federal research funding to Louisiana and deliver solutions.
Treat AI as a Teammate—or Risk Falling Behind
AI is shifting from back-office tool to frontline collaborator, "We are witnessing a key inflection point in how organizations work," says LSU professor Andrew Schwarz. He argues the business case is now clear: AI boosts the quality of ideas and expands who gets to contribute, acting less like software and more like a creative partner. He adds that organizations that embed AI "as a teammate will lead," while those that treat it "as simply a cost-saver risk falling behind." That shift, he says, reaches deep into org charts and workflows. Schwarz notes that AI can flatten expertise silos, help less-experienced employees operate closer to expert levels, and spark cross-functional thinking that blends technical and commercial insight. Leaders, he said, must "rethink structures, roles and workflows — placing AI at the heart of how teams collaborate, not simply at the edge." Technology deployment alone won't deliver those gains, "it requires cultural and capability investment," Schwarz said. The priority, in his view, is to "build collaborative ecosystems where human talent and AI capabilities co-create value," invest early to make the "human-plus-AI" model the default, and tap into academic partnerships: "those companies that partner with universities, such as LSU, will have an even greater advantage." Schwarz also urges guardrails as adoption accelerates. He points to the need for transparency, accountability, fairness, and continuous skill development so the transition "enhances human agency, fosters inclusion, and delivers sustainable value for all stakeholders." His bottom line is urgent and straightforward: "When AI joins the team, better ideas truly surface. Let's prepare our organizations to make that transition, and lead from the front."
What the First U.S. Chikungunya Virus Case Means: LSU Expert Breaks It Down
"The main vector in the US, Aedes albopictus, is known to have been there so it isn’t terribly surprising that we’d eventually have a case. The fact that is was a local transmission case – meaning that a mosquito transmitted it to someone who had not traveled outside the area – is a bit concerning and points to a couple of things: We need more surveillance for these types of viruses; the fact that it got here means likely someone who had traveled brought it back from their vacation The surveillance infrastructure via the CDC and federal funding has been gutted – which of course is problematic when we have these sorts of introductions occurring. These types of mosquitoes go a little quiet in the fall/winter because it gets too cool for them to be as active as say the summertime. They’re lucky it’s in the fall and not at the start of summer, where the weather would be more conducive to MORE transmission. HOWEVER, as weather patterns change from a combination of climate change and urban development (which creates more heated areas), we’re going to see the times that these mosquitoes are more active becoming longer – which will again mean more opportunities for transmission. Of course, in Louisiana, these mosquitoes are active for a lot of the year. We have good mosquito control, but anyone who sits outside will tell you that doesn’t eliminate biting (though imagine if we didn’t have it) we need to stay vigilant and support the systems that protect us: mosquito abatement, federal and state surveillance, and the science and research that supports our ability to recognize and respond to outbreaks." Dr. Christofferson's recent research publications in this area:
LSU Hurricane Expert Dr. Jill Trepanier Featured in TIME Magazine
For the first time in a decade, no hurricanes have made landfall in the United States through the end of September—a rare and welcome reprieve for coastal communities. But according to LSU hurricane climatologist Dr. Jill Trepanier, the season has been far from quiet. In a recent TIME Magazine feature, Trepanier explains that while no major storms have struck land, powerful systems have still formed over the Atlantic. “There are storms,” she says. “They’re just not making landfall.” Trepanier points to several atmospheric factors behind this pattern, including dry air moving in from the Sahara and a persistent high-pressure system over the Gulf of Mexico that has made conditions unfavorable for hurricane development near the U.S. coast. Another key influence, she notes, is a pressure pattern called the North Atlantic Oscillation, which helps steer storm paths. “When that oscillation pattern shifts closer to Bermuda, it unfortunately drives them directly into the Gulf Coast and the eastern seaboard,” Trepanier says. “It changes over the course of a handful of years, and then back again. It’s this controlling mechanism that has shifted, thankfully, in the favor of those of us at the coast.” Read the full article here:
Aston University: From Metformin to modern obesity therapies
Early beginnings: from herbal medicine to modern drug The origins of a modern diabetes therapy can be traced back to Galega officinalis (goat’s rue), a herb used in European folk medicine for centuries to treat excessive thirst and urination. Its active chemical, guanidine, was found to lower blood sugar in animals in 1918, inspiring the synthesis of a family of drugs known as biguanides. Among these new drugs was metformin, created in 1922 and introduced as a treatment for diabetes in Europe in the late 1950s. However, by the 1970s, metformin was largely disregarded because other biguanide medicines were being withdrawn due to their side-effect of lactic acidosis. Revival in the 1990s: Aston’s role in rediscovery In the early 1990s, research at Aston University provided a decisive turning point. Professor Cliff Bailey and his colleagues revealed that metformin’s primary action occurred in the intestine, where it promoted glucose metabolism and reduced blood sugar without causing weight gain. Their studies clarified that concerns about lactic acid were largely due to misuse, not inherent toxicity. These findings reignited global interest in metformin. Professor Bailey presented his work as an expert witness to the US Food and Drug Administration in 1994, a critical step in securing approval of the drug in the US. He also assisted the European Medicines Agency during periodic reassessments. “My research has always focused on understanding how type 2 diabetes develops and how best to treat it.” Professor Clifford Bailey, Aston University. Establishing global first-line therapy Momentum built through the late 1990s. The UK Prospective Diabetes Study (1998) demonstrated that metformin not only improved blood sugar but also reduced cardiovascular risk, strengthening the case for its wider adoption. By 2012, the American Diabetes Association and the European Association for the Study of Diabetes recommended metformin as the preferred first-line treatment for type 2 diabetes. “We discovered that metformin worked somewhat differently from what was previously thought. By showing how it could be used safely and effectively, we helped pave the way for its wider acceptance.” Today, metformin is the most prescribed diabetes drug worldwide. It is included in the World Health Organization’s Essential Medicines List and has been taken by hundreds of millions of patients, profoundly reshaping global diabetes care. New directions: dapagliflozin and the SGLT-2 inhibitors After the success of metformin, Aston played a central role in the next wave of diabetes medicines. In the 2000s, Professor Bailey was principal investigator in clinical trials for dapagliflozin, the first of the sodium-glucose co-transporter-2 (SGLT-2) inhibitors. Unlike older therapies, SGLT inhibitors lower blood sugar by blocking reabsorption of glucose in the kidneys, causing excess glucose to be excreted in urine. Large international trials demonstrated additional benefits, including weight reduction, lower blood pressure, and improved outcomes for patients with kidney and heart disease. Since its launch in 2012, dapagliflozin has become the most widely prescribed SGLT-2 inhibitor, with more than five million patients treated. It is now embedded in global treatment guidelines, expanding therapeutic options to improve the control of blood glucose and body weight. Foundations for modern obesity therapies The influence of Aston University’s research extends beyond metformin and dapagliflozin. The University’s diabetes research team also studied gut hormones such as GIP (glucose-dependent insulinotropic peptide), which play a central role in regulating insulin secretion and fat metabolism. These early discoveries helped lay the groundwork for today’s incretin-based therapies, including combined GIP/GLP-1 receptor agonists such as tirzepatide. Now widely known as 'anti-obesity injections', these medicines emerged as diabetes treatments and are now transforming care for overweight people with and without type 2 diabetes. Key findings from the research at Aston University Metformin is now being investigated for its anti-ageing and fertility benefits Dapagliflozin shows promise against heart and kidney diseases and gout Gut hormones such as GIP may hold the key to entirely new treatment strategies Why does this matter? The work by Professor Bailey and his colleagues at Aston University has contributed to metformin’s recognition as the primary treatment worldwide for type 2 diabetes. Today, at least half of all patients in Western countries are prescribed metformin — an incredibly cost-effective medicine that continues to save lives. “We identified early on that gut hormones such as GIP were central players in the control of blood glucose and body weight — long before they became the basis for today’s new generation of anti-obesity medicines.” This original research helped lay the scientific foundation for breakthrough treatments like tirzepatide, widely hailed as a game-changer in obesity and diabetes care. Aston University also contributed to the development of dapagliflozin, the first in a new class of drugs that lower blood sugar while also protecting the heart and kidneys. “Millions of people worldwide are living longer and healthier lives because of therapies that have been underpinned by research at Aston University.” Looking ahead Type 2 diabetes remains one of the world’s most pressing health challenges, affecting more than 500 million people globally. Its progressive nature demands a continual search for safer, more effective treatments. From helping rescue a nearly forgotten drug in the 1990s to shaping the next generation of therapies, Aston University’s research has left an enduring mark on clinical practice, regulation, and patient outcomes. The legacy of this work is clear: millions of people worldwide are living longer, healthier lives because of medicines that Aston helped bring to the forefront of modern diabetes and obesity care. About Cliff Bailey is Emeritus Professor of Clinical Science and Anniversary Professor at Aston University in Birmingham, England. He has served on medical and scientific committees of Diabetes UK (formerly the British Diabetic Association), Society for Endocrinology, and European Association for the Study of Diabetes. He has served as a diabetes expert for the approval of new medicines by regulatory agencies including the European Medicines Agency and NICE. His research is mainly directed towards the pathogenesis and treatment of diabetes, especially the development of new agents to improve insulin action and reduce obesity, and the therapeutic application of surrogate beta-cells. Dr Bailey has published over 400 research papers and reviews, and four books, and he is particularly known for research on metformin. References to Case Studies and Key Sources Bailey CJ et al. Metformin: Changing the Treatment Algorithm for Type 2 Diabetes. Aston University REF Impact Case Study, 2014. Bailey CJ. Metformin: Historical Overview. Diabetologia, 2017. Bailey CJ & Day C. Treatment of Type 2 Diabetes: Future Approaches. British Medical Bulletin, 2018.
Nursing researcher receives over $500K in prestigious grants
For the first time in nearly 15 years, a faculty member from Augusta University’s College of Nursing has been awarded a grant from the National Institutes of Health. Blake McGee, PhD, has secured an R03 award of $176,331 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development to study Medicaid’s expanded role in late postpartum maternal health. But he hasn’t stopped there as McGee is also part of the fifth cohort of Betty Irene Moore Fellows, a prestigious program for nurse leaders and innovators that has awarded CON half a million dollars to support his research project and leadership development. McGee, the prelicensure department chair and an associate professor, is collaborating with colleagues from other Georgia universities on both studies, which are occurring simultaneously. “I began my career as an ER nurse and have always wanted to ask bigger questions about the challenges facing patients and how we might best address them as a society,” said McGee, who was recently selected for publication in Blood Advances, the American Society of Hematology’s journal. “As nursing scientists, we are uniquely poised to ask questions about healthcare policy, specifically from the vantage point of the impact that policy choices have on patients and their health outcomes.” This century, the United States has seen rising maternal mortality rates with alarming racial disparities. Over half of these deaths occur in the postpartum period, with 23% occurring more than six weeks after delivery. Medicaid expansion covers pregnant women in households below 138% of the Federal poverty level through postpartum day 60, which has been associated with decreased mortality and reduced racial disparity in maternal death. At the time of grant submission, pregnancy Medicaid eligibility traditionally lapsed 60 days after delivery, leaving postpartum people vulnerable to disruptions in care. McGee’s work aims to identify changes in maternal health care use and health outcomes 60 days to 1 year after delivery that were associated with state Medicaid expansions (2007–19). The team will examine whether the effects of expansion vary by maternal race or ethnicity and will explore whether patient-reported health care access and quality mediate the relationships between expansion and outcomes. “My hope is that after the study we’ll have a better understanding of how health and health care use change for women in this crucial late postpartum period and how they may differ for people of different backgrounds,” said McGee. “Due to the sample design, findings will reliably inform optimal policy for postpartum coverage duration.” He expects this study to provide preliminary data for a future R01-funded study that directly examines the impact of extending the duration of postpartum Medicaid under the American Rescue Plan. As part of the Betty Irene Moore Fellowship, McGee is one of 15 fellows across the nation in a curriculum co-delivered by the UC Davis School of Nursing and Graduate School of Management. A project coordinator from AU’s School of Public Health will also assist with the fellowship project. McGee hopes to involve graduate research assistants or recent alumni as research associates on the team. Specifically, McGee will be studying the Georgia Pathways to Coverage Program, making him one of the only academic researchers in the nation funded to do so. “As a researcher, it is always a privilege to engage in topics that directly impact the current state of health care, and I’m honored to tackle projects that are so relevant to today’s health policy headlines,” he said. Georgia stands out among other states that are exploring an extension of Medicaid to low-income, working-age adults who demonstrate a monthly commitment of 80 hours to an employment-related activity. By studying the effects of this program, McGee predicts the findings will be highly relevant to anticipating the impact of recent Medicaid changes at the federal level and may indicate differences between Pathways participants and those who might qualify but remain uninsured. This focus could provide data that helps the state target enrollment efforts. The state’s own logic model predicts that the program will reduce hospitalizations, and McGee is eager to determine the program’s success. “Our findings should be helpful to the state to better understand those enrolling, what their experience with increased access to care has been and how their health has improved after receiving coverage,” McGee said.
Supporting the development of advanced computing hardware, the National Science Foundation (NSF) awarded Supriyo Bandyopadhyay, Ph.D., Commonwealth Professor in the Department of Electrical and Computer Engineering at the Virginia Commonwealth University (VCU) College of Engineering with more than $300,000 to develop processor-in-memory architecture using quantum materials. “This is one of the first mainstream applications of quantum materials that have unusual and unique quantum mechanical properties,” Bandyopadhyay said. “Quantum materials have been researched for more than a decade and yet there is not a single mainstream product in the market that utilizes them. We want to change that.” The four-year project, titled “Collaborative Research, Foundations of Emerging Technologies: PRocessor In Memory Architecture based on Topological Electronics (PRIMATE),” aims to advance computing hardware and artificial intelligence by integrating topological insulators and magnetic materials. Topological insulators are a special material with an electrically conductive surface and an insulated interior. They have special quantum mechanical properties like “spin-momentum locking,” which ensures the quantum mechanical spin of an electron-conducting current on the surface of the material is always perpendicular to the direction of motion.This marks the first time such quantum materials will be used in a processor-in-memory system. “We place a magnet on top of a topological insulator,” Bandyopadhyay said. “We then change the magnetization of the magnet by applying mechanical strain on it. That changes the electrical properties of the topological insulator via a quantum mechanical interaction known as exchange interaction. This change in the electrical properties can be exploited to perform the functions of a processor-in-memory computer architecture. The advantage is that this process is fast and extremely energy-efficient.” If successful, this approach could reduce energy use and dramatically speed up computing by moving data processing into the memory itself. It addresses the longstanding “memory bottleneck,” the slowdown caused by computers constantly needing to move data back and forth between processor and memory. These efficiencies could make advanced AI more efficient and accessible, paving the way for the first commercially viable applications of quantum materials.. The research is a collaboration with University of Virginia professors Avik Ghosh and Joseph Poon. A VCU Ph.D. student will work on the project and receive training in fabrication, characterization and measurement techniques, preparing them to lead in the rapidly evolving field of computing hardware.
The e-learning resource, Supporting people living with long COVID, was developed by the Centre for Pharmacy Postgraduate Education (CPPE) It is designed to help community pharmacy teams build their skills, knowledge and confidence The programme offers video and audio resources, practical consultation examples and strategies for supporting individuals. Professor Ian Maidment at Aston Pharmacy School has been involved in a project with the Centre for Pharmacy Postgraduate Education (CPPE) to develop a new e-learning programme for community pharmacists, called Supporting people living with long COVID. The programme is designed to help community pharmacy teams build their skills, knowledge and confidence to support people managing the long-term effects of COVID-19. It was developed with researchers undertaking the National Institute for Health and Care Research (NIHR)-funded PHARM-LC research study: What role can community PHARMacy play in the support of people with long COVID? During the development of the e-learning resource, as well as with Professor Maidment, CPPE worked in collaboration with researchers from Keele University, the University of Kent, Midlands Partnership University NHS Foundation Trust and lechyd Cyhoeddus Cymru (Public Health Wales). The research draws on lived experience of long COVID, as well as the views of community pharmacy teams on what learning they need to better support people living with the condition. This new programme offers video and audio resources, practical consultation examples and strategies for supporting individuals through lifestyle advice, person-centred care and access to wider services. Professor Maidment said: “As an ex-community pharmacist, community pharmacy can have a key role in helping people living with long COVID. The approach is in line with the NHS 10 Year Health Plan, which aims to develop the role of community pharmacy in supporting people with long-term conditions.” Professor Carolyn Chew-Graham, professor of general practice research at Keele University, said: “Two million people in the UK are living with long COVID, a condition people are still developing, which may not be readily recognised, because routine testing for acute infection has largely stopped. For many, the pharmacy is the first place they seek advice about persisting symptoms following viral infection. The pharmacy team, therefore, has the potential to play a really important role in supporting people with long COVID. This learning programme provides evidence-based information to develop the confidence of pharmacy staff in talking to people with long COVID. Developed with people living with long COVID, the programme’s key message is to believe and empathise with people about their symptoms.” Visit www.cppe.ac.uk/programmes/l/covid-e-01 to access the e-learning programme. This project is funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number NIHR205384).
